Ignite Creation Date:
2024-05-06 @ 12:26 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03760445
Status:
WITHDRAWN
Last Update Posted:
2020-01-09
First Post:
2018-11-13
Brief Title:
HDM201 Added to CT in RR or Newly Diagnosed AML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Leukemia Myeloid Acute |
Keywords:
| Name | View |
|---|---|
| DDI with sensitive CYP3A4 substrate | View |
| HDM201 | View |
| midostaurin | View |
| cytarabine | View |
| daunorubicin | View |
| idarubicin | View |
| liposomal cytarabinedaunorubicin | View |
| acute myeloid leukemia AML | View |
| 1L newly diagnosed AML | View |
| relapsedrefractory AML | View |
| FLT3-mutation | View |
| combination treatment | View |
| dose escalation | View |
| CRCRi | View |
| minimal residual disease | View |
| DDI with CYP3A4 inhibitors | View |